Kristen Oelschlager Sells 8,587 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,587 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $20.71, for a total transaction of $177,836.77. Following the completion of the transaction, the chief operating officer owned 30,460 shares of the company’s stock, valued at approximately $630,826.60. This trade represents a 21.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 4.3%

Shares of CSTL stock traded up $0.87 during trading hours on Thursday, hitting $21.12. 720,100 shares of the company’s stock traded hands, compared to its average volume of 397,471. The stock has a market cap of $640.57 million, a PE ratio of -48.00 and a beta of 1.04. The stock’s 50 day simple moving average is $21.90 and its 200 day simple moving average is $29.91. The company has a quick ratio of 6.53, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). The company had revenue of $84.23 million for the quarter, compared to analysts’ expectations of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. On average, sell-side analysts anticipate that Castle Biosciences, Inc. will post -1.4 EPS for the current year.

Institutional Trading of Castle Biosciences

A number of institutional investors have recently bought and sold shares of CSTL. Federated Hermes Inc. acquired a new stake in Castle Biosciences during the 4th quarter worth about $26,000. Kemnay Advisory Services Inc. acquired a new position in shares of Castle Biosciences in the 4th quarter valued at about $35,000. Jones Financial Companies Lllp lifted its stake in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after purchasing an additional 976 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Canaccord Genuity Group reduced their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Robert W. Baird lowered their price objective on Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. KeyCorp set a $35.00 price objective on Castle Biosciences in a research note on Friday, May 29th. Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Finally, Wall Street Zen downgraded shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $42.83.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.